Analysis

Ac Immune Sa (IMR) Stock Analysis

Ac Immune Sa investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to IMR.

websiteIMR/analysis/IMR

Ac Immune Sa

Ac Immune Sa investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to IMR.

Stock profile

Ticker

IMR

Asset type

Stock

Market cap

$244.3M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

EUR

Ticker listings

Ac Immune Sa may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ACIU primary listing
  • IMR primary listing
  • A2AR5F

Latest Ac Immune Sa news

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104...

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43...

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenureBoard Chair, Martin ...

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD resul...

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in AB...

Research sections

Valuation

Review valuation context for Ac Immune Sa.

Future growth

Review future growth context for Ac Immune Sa.

Past performance

Review past performance context for Ac Immune Sa.

Financial health

Review financial health context for Ac Immune Sa.

Dividend

Review dividend context for Ac Immune Sa.

Management

Review management context for Ac Immune Sa.

Ownership

Review ownership context for Ac Immune Sa.

Other information

Review other information context for Ac Immune Sa.

Community

Review community context for Ac Immune Sa.